Filing Flows › Sanofi (SNY) › Q3 2026
Sanofi (SNY) Q3 2026 earnings results (third quarter 2026)
6-K filed Oct 30, 2026
Sanofi (SNY) reported revenue of $14.4B for the third quarter 2026 (Q3 2026), +16% from a year earlier. Operating margin was 30.1%, net earnings $3.0B (21.0% of revenue).
Sanofi, Q3 2026: revenue $14.4B (+16% year over year), operating margin 30.1%, net earnings $3.0B. The chart follows the revenue to costs, profit and cash.
| Q3 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $14.4B | — | +16% |
| Gross profit | $11.6B | — | +19% |
| Operating profit | $4.3B | — | +20% |
| Net earnings | $3.0B | — | +8% |
What changed
Revenue was €14.4B in Q3 2026, up 16% year over year. Sales at constant exchange rates was the largest line at 98% of revenue.
Gross margin was 80.3%, up 1.8 points from a year earlier. Operating profit was €4.3B, a 30.1% margin (up 1.0 points year over year). Of the extra revenue versus a year earlier, 36% reached operating profit, above the 29% margin then. Operating expenses grew 18% against revenue growth of 16%. The fastest-growing cost line was Other operating costs (+26%). Net earnings were €3.0B, up 8% year over year. The effective tax rate was -65.2%.
Questions
What was Sanofi's revenue in the third quarter 2026?
Sanofi (SNY) reported revenue of $14.4B for the third quarter 2026 (Q3 2026), +16% from a year earlier.
Was Sanofi profitable in the third quarter 2026?
Operating profit was $4.3B (30.1% of revenue) and net earnings $3.0B.
Source: Sanofi 6-K on SEC EDGAR.